access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook lock solid find a provider find a clinical trial find a provider find a researcher find faculty find-a-service how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next chevron right nxt prev pay your bill play previous quality and safety refer a patient request a speaker request appointment request an appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker Arrow Circle Up twitter youtube Dino Logo External Link University Logo Color University Logo Solid Health Logo Solid Arrow Right Circle Book Calendar Date Calendar Search Date Diploma Certificate Dollar Circle Donate Envelope Graduation Cap Map Pin Map Search Phone Pills Podcast
Image of liver cells

Proteomics Core

The objective of this Core is to provide state-of-the-art mass spectrometry-based proteomic capabilities to MUSC DDRC investigators. It provides not only mass spectrometry to allow the discovery of the effects of drugs/ligands, genetic alterations, and disease on changes in protein expression, protein interactions, and post-translational modifications, but in a highly unique and innovative component, it provided MS-imaging.

This Core has extensive experience in investigation of post-translational modifications and thus provides investigators the opportunity to investigate responses to ligand stimulation by examining protein function, half-life, and localization. To provide the services of this DDRC Core in a cost-effective manner, existing MUSC Mass Spectrometry Facility resources (including an extensive array of instrumentation) are leveraged. Unique for the DDRC, this Core also has expertise and an innovative track record in mass spectrometry based imaging of tissue in situ. As alterations in extracellular matrix proteins are a hallmark of many digestive diseases, this attribute is highly relevant to the community. Lastly, through our expertise in developing mass spectrometry based imaging, we provide MS-imaging technologies for the analysis of metabolites, lipids, glycolipid and glycans in tissue.

Core Leader:

Richard R. Drake, Ph.D.